PSTI - Pluristem Therapeutics, Inc. Summary, Stock Quote and News

3.410 -0.09 (-2.57%)

Data as of Dec 15, 2019

Prev. Close 3.5
Price Open 3.51
Volume 23,340
Day's Range 3.38 - 3.51
52 Wk Range 3.11 - 11.9
50 Day Moving Avg. 3.49
PE Ratio 0
Shares Outstanding 15.71M
Market Cap 53.58M

Trade PSTI stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
7/31/18	B. Riley FBR	Initiates Coverage On	Buy	4.5
10/06/17	Seaport Global	Initiates Coverage On	Buy	5.0
6/19/17	Maxim Group	Upgrades	HoldBuy

19 Healthcare Stocks Moving In Tuesday's Pre-Market Session Lisa LevinTue, 03 Dec 2019 07:46:51 -0500
Pluristem Completes 50% Enrollment In Phase III PLX-PAD Muscle Injury Study Benzinga NewsdeskTue, 03 Dec 2019 07:08:27 -0500
9 Healthcare Stocks Moving In Friday's Pre-Market Session Lisa LevinFri, 29 Nov 2019 07:43:47 -0500
24 Stocks Moving in Friday's Pre-Market Session Lisa LevinFri, 29 Nov 2019 07:39:32 -0500
Pluristem Therapeutics Granted European Patent Number EP2697362 Titled "Methods And Systems For Harvesting Cells" Benzinga NewsdeskWed, 27 Nov 2019 11:23:42 -0500
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Shanthi RexalineWed, 20 Nov 2019 07:25:05 -0500
The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Shanthi RexalineTue, 19 Nov 2019 07:56:14 -0500
The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing Shanthi RexalineThu, 14 Nov 2019 08:07:04 -0500
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Shanthi RexalineFri, 08 Nov 2019 08:14:09 -0500
Watching Pluristem Shares Following Tweet From Patent Grants Highlighting WIPO PatentScope Application For 'use of specialized vessels for formulating and dispensing pharmaceutical formulations' Benzinga NewsdeskThu, 24 Oct 2019 08:52:09 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment Globe NewswireDec 03, 2019
Pluristem Therapeutics CEO Issues Shareholder Update Globe NewswireNov 12, 2019
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare Globe NewswireNov 04, 2019
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs Globe NewswireSep 16, 2019
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs Globe NewswireSep 09, 2019
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results PRNewswireAug 28, 2019
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs Globe NewswireAug 21, 2019
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome Globe NewswireJul 31, 2019
Pluristem Therapeutics' CEO Issues Shareholders Update Globe NewswireJul 24, 2019
Pluristem Announces One-for-Ten Reverse Split of its Common Shares Globe NewswireJul 24, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 5…% Enrollment GuruFocusDec 03, 2019
Key events next week - healthcare Seeking AlphaSep 13, 2019
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and ... GuruFocusSep 09, 2019
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and ... GuruFocusAug 21, 2019
Pluristem up 2% premarket on positive PLX-R18 data Seeking AlphaJul 31, 2019
Pieris Pharmaceuticals and Pluristem Therapeutics among healthcare gainers; Lexicon Pharmaceuticals leads the losers Seeking AlphaJul 29, 2019
Key events this week - healthcare Seeking AlphaJul 28, 2019
Pluristem Therapeutics' CEO Issues Shareholders Update GuruFocusJul 24, 2019
Pluristem (-23%) to reverse split shares 1:10 Seeking AlphaJul 24, 2019
Sell-siders bullish on BridgeBio in premarket analyst action Seeking AlphaJul 22, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q4 2019	EST	Actual	Surprise
EPS:	Expected 2019-09-12
Rev:	Expected 2019-09-12

Q1 2020	EST	Actual	Surprise
EPS:	Expected 2019-12-27
Rev:	Expected 2019-12-27

Company Profile

Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. Pluristem operates through the single business segment being Development of placenta-based cell therapy product.

Brokerage Center

Compare All Online Brokerages

Market Overview

Pluristem Therapeutics, Inc. PSTI:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Pluristem Therapeutics, Inc. PSTI:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners